ArticleBritish journal of cancer2001
Effects of the combination of camptothecin and doxorubicin or etoposide on rat glioma cells and camptothecin-resistant variants.
Article in British journal of cancer, 2001. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 59 citations in OpenAlex.
- Integrated Workflow for Drug Repurposing in Glioblastoma: Computational Prediction and Preclinical Validation of Therapeutic Candidates.Brain sciences · 2025Article
- Coronary microcirculation damage in anthracycline cardiotoxicity.Cardiovascular research · 2022Article
- Hyaluronic acid conjugates for topical treatment of skin cancer lesions.Science advances · 2021Article
- Role of synergy and immunostimulation in design of chemotherapy combinations: An analysis of doxorubicin and camptothecin.Bioengineering & translational medicine · 2019Article
- Role of Endothelium in Doxorubicin-Induced Cardiomyopathy.JACC. Basic to translational science · 2018Review
- Preparation of a mesoporous silica-based nano-vehicle for dual DOX/CPT pH-triggered delivery.Drug delivery · 2018Article
- Topoisomerase II Poisons for Glioblastoma; Existing Challenges and Opportunities to Personalize Therapy.Frontiers in neurology · 2018Review
- Inactivation of nuclear factor κB by MIP-based drug combinations augments cell death of breast cancer cells.Drug design, development and therapy · 2018Article
- Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.Molecular therapy. Nucleic acids · 2017Review
- Screening of Chonemorpha fragrans Bioactive Extracts for Cytotoxicity Potential and Inhibition Studies of Key Enzymes Involved in Replication.Pharmacognosy magazine · 2016Article
- Synergistic antitumor activity of camptothecin-doxorubicin combinations and their conjugates with hyaluronic acid.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- Multifunctional enveloped mesoporous silica nanoparticles for subcellular co-delivery of drug and therapeutic peptide.Scientific reports · 2014Article
- Folding graft copolymer with pendant drug segments for co-delivery of anticancer drugs.Biomaterials · 2014Article
- Codelivery of doxorubicin and paclitaxel by cross-linked multilamellar liposome enables synergistic antitumor activity.Molecular pharmaceutics · 2014Article
- A phase I study of irinotecan and pegylated liposomal doxorubicin in recurrent ovarian cancer (Tohoku Gynecologic Cancer Unit 104 study).Cancer chemotherapy and pharmacology · 2014Article
- Treatment of colorectal cancer using a combination of liposomal irinotecan (Irinophore C™) and 5-fluorouracil.PloS one · 2013Article
- Antitumor agents 294. Novel E-ring-modified camptothecin-4β-anilino-4'-O-demethyl-epipodophyllotoxin conjugates as DNA topoisomerase I inhibitors and cytotoxic agents.Bioorganic & medicinal chemistry · 2012Article
- Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model.Journal of materials science. Materials in medicine · 2010Article
- Pharmacotherapy for adults with tumors of the central nervous system.Pharmacology & therapeutics · 2009Review
- Exposure to low concentrations of etoposide reduces the apoptotic capability of leukaemic cell lines.Leukemia · 2002Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
From the rat C6 glioma cell line in culture, we selected camptothecin-resistant variants by growth in the presence of increasing amounts of this drug (C6(CPT10), C6(CPT50)and C6(CPT100), growing respectively with 10, 50 and 100 ng ml(-1)camptothecin). The degree of resistance to camptothecin ranged between 15-fold (C6(CPT10)) and 30-fold (C6(CPT50)and C6(CPT100)). The C6(CPT10)cell line presented a collateral sensitivity to etoposide (3.6-fold), while the C6(CPT50)and C6(CPT100)cell lines were cross-resistant to etoposide (1.8-fold) The resistant lines were characterised by a two-fold reduced content and catalytic activity of topoisomerase I, and C6(CPT50)and C6(CPT100)presented a significant increase in topoisomerase IIalpha content and catalytic activity and a marked overexpression of P-glycoprotein. We explored the cytotoxicity of combinations of a topoisomerase I inhibitor (camptothecin) and a topoisomerase II inhibitor (doxorubicin or etoposide) at several molar ratios, allowing the evaluation of their synergistic or antagonistic effects on cell survival using the median effect principle. The simultaneous combination of camptothecin and doxorubicin or etoposide was additive or antagonistic in C6 cells, slightly synergistic in the C6(CPT10)line and never more than additive in the C6(CPT50)and C6(CPT100)cell lines. The sequential combination of doxorubicin and camptothecin gave additivity in the order camptothecin --> doxorubicin and antagonism in the order doxorubicin --> camptothecin. Clinical protocols combining a topoisomerase I and a topoisomerase II inhibitor should be considered with caution because antagonistic effects have been observed with combinations of camptothecin and doxorubicin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.